Marrow Therapeutics
Developer of antibody-drug conjugate treatments for sickle cell disease and beta thalassemia.
Marrow Therapeutics is a biotech & life sciences company based in Watertown, US. It has raised $173 million in disclosed funding. Its latest round was a Series B of $173 million in November 2026.
Overview
No overview yet. It is written from sources once there are enough of them.
Funding
Total disclosed: $173M across 1 round. Computed only from sourced rounds.
| Date | Company | Amount | Stage | Lead | Other investors | Sector | Sources |
|---|---|---|---|---|---|---|---|
| $173M | Series B | Scion Life Sciences, Venbio Partners, OrbiMed | RTW Investments +7 | Biotech & Life Sciences | 1 |
Nov 17 · Series B
Marrow Therapeutics$173MLed by Scion Life Sciences, Venbio Partners, OrbiMed · with RTW Investments, +7
Investors
Questions and answers
What does Marrow Therapeutics do?
Developer of antibody-drug conjugate treatments for sickle cell disease and beta thalassemia.
How much has Marrow Therapeutics raised?
Marrow Therapeutics has raised $173 million in disclosed funding across 1 round tracked by OSH.
Who has invested in Marrow Therapeutics?
Investors in Marrow Therapeutics include Scion Life Sciences, Venbio Partners, OrbiMed, RTW Investments, Surveyor Capital and 6 more.
When and where was Marrow Therapeutics founded?
Marrow Therapeutics and is based in Watertown, US.
Sources
- 1.Sickle Cell Drug: Marrow Raises $173 Million Without Releasing Anemia or Selectivity Data — techtimes.com, Nov 17, 2026